Aerie Pharmaceuticals Inc Net Income per Employee (AERI), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Aerie Pharmaceuticals Inc   (NASDAQ: AERI)
 

Aerie Pharmaceuticals Inc Net Income per Employee

AERI's Quarterly Results, Trends, Rankings, Statistics
Aerie Pharmaceuticals Inc recorded a cumulative net loss of $-37 million during 12 month ending in the third quarter 2022.
The Healthcare sector has seen employees of 37 other companies achieving higher income per employee. While Aerie Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 3512.


What is Income per Employee Ratio?






AERI Net Income per Employee (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -141,139 -190,811 -265,394 -288,842 -642,780
AERI's Total Ranking # 3512 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


AERI Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 38
Healthcare Sector # 400
Overall Market # 3512

Net Income per Employee Statistics
High Average Low
$ -141,139 $ -580,329 $ -925,950
(Sep 30 2022)   (Mar 31 2019)







Companies with similar Income per Employee for 12 month ending Sep 30 2022, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2022Number of Employees Sep 30 2022


Date modified: 2026-08-29T17:18:16+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.